The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Omeros Corporation (Nasdaq: OMER) ("Omeros" or the "Company") announced that on July 24, 2025 it entered into a securities ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

According to DelveInsight's analysis, the intermediate AMD market size is anticipated to grow with a significant CAGR during ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Sobi will pay partner Apellis $275 million up front and $25 million in potential milestones to reduce its ex-U.S. royalty obligations on Empaveli.

Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis’ balance sheet Apellis ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the most promising stocks according to Wall Street analysts. On July 1, Apellis Pharmaceuticals announced a capped royalty purchase agreement with ...